IP Library Granted Patent US 8,268,988
Granted Patent B2
US 8,268,988 · App. 13/092,812 · Granted Sep 18, 2012

Process for preparing an A2A-adenosine receptor agonist and its polymorphs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,268,988
App. No.
13/092,812
Granted
Sep 18, 2012
Kind
B2
Abstract

Disclosed is a synthesis suitable for large scale manufacture of an A 2A -adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.

Claims (45)

1. A method of synthesizing Compound A having the formula:

comprising:

(a) contacting compound 1 having the formula:

with a 14.3-16.7 fold molar excess of hydrazine to provide compound 2 having the formula:

(b) contacting compound 2 with an excess of ethyl 2-formyl-3-oxopropionate to provide compound 4 having the formula:

(c) contacting compound 4 with methylamine.

2. The method of claim 1 , further comprising wherein the hydrazine in (a) is first heated to approximately 60-65° C. followed by addition of compound 1.

3. The method of claim 1 , further comprising wherein compound 2 is isolated by:

cooling the reaction mixture to approximately 40° C.;

adding a 4.2-4.9 mass equivalent of water while maintaining the temperature at approximately 40° C.; and

cooling the mixture to approximately 10° C. and maintaining at that temperature for at least approximately 1 hour.

4. The method of claim 3 , further comprising:

filtering the isolated compound 2;

washing the contents of the filter with water followed by ethanol; and

drying the solid that remains under vacuum at a temperature that does not exceed 30° C. for at least 12 hours.

5. The method of claim 1 , wherein the excess ethyl 2-formyl-3-oxoproionate is about a 5-10 fold molar excess.

6. The method of claim 1 , wherein the excess ethyl 2-formyl-3-oxoproionate is about a 6.8-7.5 fold molar excess.

7. The method of claim 1 , wherein (b) further comprises adding HCl as a catalyst.

8. The method of claim 7 , wherein the HCl is added in an amount of about 0.1 equivalents or less.

9. The method of claim 7 , wherein the HCl is added in an amount of about 0.05 equivalents.

10. The method of claim 1 , further comprising wherein (b) is carried out at about 80° C. and further comprises ethanol as a solvent.

11. The method of claim 1 , further comprising wherein compound 4 is isolated by

cooling the completed reaction mixture to approximately 10° C.;

filtering;

washing the contents of the filter with ethanol; and

drying the solid that remains under vacuum at a temperature that does not exceed 40° C.

12. The method of claim 1 , further comprising wherein (c) is carried out at approximately 2.5-7.5° C.

13. The method of claim 1 , further comprising wherein Compound A is isolated by

degassing under vacuum at not more than 35° C. to remove excess methylamine;

releasing the vacuum and cooling to 0-5° C. for approximately 15-minutes to an hour;

filtering the slurry formed;

washing the contents of the filter with water followed by ethanol; and

drying the solid that remains under vacuum at a temperature that does not exceed 40° C.

14. The method of claim 13 , further comprising wherein the Compound A is further purified by

(i) dissolving the dried solid in a solvent;

(ii) filtering any solid impurities from the solution;

(iii) rinsing with additional solvent;

(iv) adding solution to purified water that is maintained at approximately 78-88° C. thereby forming a slurry;

(v) stirring the slurry;

(vi) cooling the slurry;

(vii) filtering;

(viii) washing the contents of the filter with water followed by ethanol; and

(ix) drying the solid that remains under vacuum at a temperature that does not exceed 40° C.

15. The method of claim 14 , further comprising wherein the solvent used in (i) and (iii) comprises dimethylsulfoxide.

16. The method of claim 14 , wherein the residual water content of the Compound A product is not more than 5.5% and the residual ethanol of the Compound A product is not more than 2000 ppm.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2013
From: LEMONS, TRAVIS; SEEMAYER, ROBERT
To: GILEAD SCIENCES, INC.
Reel/Frame 029716/0839 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2011
From: ZABLOCKI, JEFF; ELZEIN, ELFATIH
To: GILEAD SCIENCES, INC.
Reel/Frame 026759/0460 →
MERGER Recorded Jun 13, 2011
From: APEX MERGER SUB, INC.; CV THERAPEUTICS, INC.
To: GILEAD PALO ALTO, INC.
Reel/Frame 026431/0101 →